<DOC>
	<DOCNO>NCT02134184</DOCNO>
	<brief_summary>In study try understand whether previous infection particular virus , namely cytomegalovirus ( CMV ) , influence ability immune system respond new infection vaccination age .</brief_summary>
	<brief_title>The Influence Chronic CMV Infection Influenza Vaccine Responses</brief_title>
	<detailed_description>The investigator want compare T- B-cell response conventional intramuscular trivalent influenza vaccine ( TIV ) elderly individual dependent presence duration CMV infection analyse vaccine-induced plasmablast , antibody antigen-specific T cell . Healthy volunteer , &gt; 60 year age , identify Stanford Blood Center base history positive negative CMV serology . Baseline blood sample draw study participant prior immunization . All participant receive single dose 2012-2013 licensed TIV . Volunteers complete 3 study visit Day 0 , Day 7 Day 28 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Otherwise healthy , ambulatory adult 60 year age . Selfidentified participant notification Stanford Blood Center ( SBC ) group assignment base review SBC CMV data : CMVnegative : Donor donate least twice last 3 year AND donor 's recent two donation test CMV antibody negative . CMV positive longstanding infection : Donor donate least within `` recent '' timeframe ( past three year ) AND donor 's recent donation test CMV antibody positive AND donor least one donation prior 2000 test CMV antibody positive . Recent CMV converter : Donor donate least within `` recent '' timeframe ( past three year ) AND donor 's recent two donation test CMV antibody positive AND donor least two CMV negative donation past . Willing complete informed consent process . Availability followup plan duration study least 28 day immunization . Acceptable medical history review inclusion/exclusion criterion vital sign . Prior offstudy vaccination current 20122013 seasonal influenza vaccine Allergy egg egg product , vaccine component thimerosal ( TIV multidose vial ) Lifethreatening reaction previous influenza vaccination . Active systemic serious concurrent illness , include febrile illness day vaccination Weight le 110 lbs History immunodeficiency ( include HIV infection ) Known suspect impairment immunologic function , include , limited , clinically significant liver disease , diabetes mellitus treat insulin , moderate severe renal disease , chronic disorder , opinion investigator , might jeopardize volunteer safety compliance protocol . Blood pressure &gt; 150 systolic &gt; 95 diastolic first study visit Hospitalization past year congestive heart failure emphysema . History chronic Hepatitis B C. Recent current use immunosuppressive medication , include systemic glucocorticoid ( corticosteroid nasal spray topical steroid permissible group ) Malignancy , squamous cell basal cell skin cancer ( include solid tumor breast cancer prostate cancer recurrence past year , hematologic cancer leukemia ) . Autoimmune disease ( include rheumatoid arthritis treat immunosuppressive medication Plaquenil , methotrexate , prednisone , Enbrel ) , opinion investigator , might jeopardize volunteer safety compliance protocol . History blood dyscrasia , renal disease , hemoglobinopathies require regular medical follow hospitalization precede year Use anticoagulation medication Coumadin Lovenox , antiplatelet agent aspirin ( except 325 mg aspirin per day ) , Plavix , Aggrenox must review investigator determine would affect volunteer 's safety . Receipt blood blood product within past 6 month plan receipt blood product prior completion study visit . Medical psychiatric condition occupational responsibility preclude participant compliance protocol Inactivated vaccine 14 day prior vaccination plan nonstudy vaccination prior completion Visit 03 ( ~Day 28 study vaccination ) Live , attenuate vaccine within 60 day vaccination plan nonstudy vaccination prior completion Visit 03 ( ~Day 28 study vaccination ) Need allergy immunization ( postpone ) study period V01 V03 ( ~Day 28 ) History GuillainBarr√© Syndrome Use investigational agent within 30 day prior enrollment plan use investigational agent prior completion study visit Donation equivalent unit whole blood within 6 week unit platelet within 2 week prior enrollment plan blood donation prior completion study visit . Any condition , opinion investigator , might interfere volunteer safety , study objective ability participant understand comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>